Jasper Therapeutics, Inc. - Class A Common Stock JSPR 深 滬
已收盤 07-18 16:00:00 美东时间
3.33
-0.040
-1.19%
華盛通- 最 高3.48
- 今 開3.40
- 成交量 35.03万股
- 最 低 3.2639
- 昨 收 3.37
- 總市值 5002.36万
- 52周最高 26.05
- 市盈率 靜 --
- 換手率 2.33%
- 52周最低 2.265
- 委 比 26.52%
- 總股本 1502.21万
- 歷史最高 188.80
- 量 比 0.79
- 振 幅 6.41%
- 歷史最低 2.265
- 每 手 1
- 風險率 7.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jasper Therapeutics Announces Major Corporate Reorganization
Jasper Therapeutics ( ($JSPR) ) has provided an update. On July 8, 2025, Jasper...
07-09 20:29
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
Jasper Therapeutics announced a corporate reorganization to extend its cash runway, including a workforce reduction of approximately 50%. Dr. Edwin Tucker is departing as Chief Medical Officer, and Dr. Daniel Adelman will serve as Acting Chief Medical Officer. The company is focusing on its briquilimab programs in chronic urticaria and halting other clinical and preclinical programs.
07-09 12:00
美股大行评级 | 潜在涨幅687%！ 花旗上调新氧科技目标价升至5.5美元，评级"买入"
今日重点评级关注：B. Riley证券：维持内克塔治疗"买入"评级，目标价从60美元升至85美元；Oppenheimer：维持Praxis Precision Medicine"跑赢大市"评级，目标价从97美元升至115美元
07-09 09:26
美股大行评级 | 潜在涨幅199.47%！杰富瑞上调Cogent Biosciences目标价至28美元，维持"买入"评级
今日重点评级关注：杰富瑞：维持Cogent Biosciences"买入"评级，目标价从23美元升至28美元；Leerink Partners：维持Cogent Biosciences"跑赢大市"评级，目标价从16美元升至18美元
07-08 09:34
William Blair Downgrades Jasper Therapeutics to Market Perform
William Blair analyst Matt Phipps downgrades Jasper Therapeutics (NASDAQ:JSPR) from Outperform to Market Perform.
07-08 05:20
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 171.6% to $27....
07-07 20:07
Jasper Therapeutics Reports Promising Briquilimab Study Results
Jasper Therapeutics ( ($JSPR) ) has provided an update. On July 7, 2025, Jasper...
07-07 19:55
Jasper Reports 89% Response Rate in Urticaria Study, Halts Asthma Program After Drug Lot Issue
Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as
07-07 19:33
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
Jasper Therapeutics reported updated data from its BEACON Phase 1b/2a study of subcutaneous briquilimab in adult patients with chronic spontaneous urticaria (CSU). The 240mg and 360mg single-dose cohorts showed strong efficacy, with 89% achieving complete response. The 180mg Q8W open-label extension study also demonstrated robust results, with 73% achieving complete response at 12 weeks. However, results from the 240mg Q8W and 240mg followed by 1...
07-07 11:30
Jasper Therapeutics Reports Positive Phase 1b/2a Study Results
Jasper Therapeutics ( ($JSPR) ) just unveiled an announcement. On June 14, 2025...
06-16 18:48
